Glioblastoma (GBM) remains incurable with median survival of 15–20 months under standard care. Early, staged prognostic discussions addressing incurability, life expectancy, and cognitive decline are essential for informed decision-making and advance care planning.
Background
GBM is an aggressive brain cancer with limited treatment advances since 2009 and a guarded prognosis after recurrence. Standard care includes surgery, radiation, temozolomide, and tumor treating fields aimed at prolonging survival and preserving quality of life. Cognitive decline is a hallmark of disease progression, often impairing patients' decision-making capacity. Early, explicit prognostic disclosure by neuro-oncologists is critical to support patient autonomy and shared decision-making.
Data Highlights
Median overall survival (OS) for GBM patients undergoing standard care: 15–20 months. Median OS after recurrence: 8–9 months. More than half of GBM patients lack awareness of their life expectancy following clinic visits. Only 37% of oncologists provide frank survival estimates when requested by patients with cancer. ASCO recommends prognosis discussion within one month of terminal cancer diagnosis.
Key Findings
GBM prognosis discussions should include incurability, estimated life expectancy, and impending cognitive decline.
Early disclosure of incurability and cognitive decline is recommended at first consultation; life expectancy discussion can be staged to subsequent visits.
There is significant variability and inconsistency in prognostic communication among neuro-oncologists.
Many patients remain unaware of their prognosis and disease trajectory despite clinic visits.
Oncologists often avoid early prognostic conversations due to fear of diminishing patient hope.
Hope is linked to better physical and mental health, but withholding prognosis can impair informed consent and advance care planning.
Clinical Implications
Neuro-oncologists should adopt a staged approach to prognostic disclosure, balancing honesty with emotional sensitivity to preserve hope while ensuring informed consent. Early conversations about incurability and cognitive decline enable timely advance care planning before patients lose decision-making capacity. Awareness of patient preferences and clinical trajectory should guide individualized communication strategies.
Conclusion
A structured, compassionate framework for staged prognostic discussions in GBM can improve patient understanding, support autonomy, and optimize care planning. Integrating cognitive decline prognosis alongside survival estimates is crucial given the disease’s impact on decision-making capacity.
References
Stupp et al. 2009 -- Standard of care and survival in GBM
Weller et al. 2017 -- Advances and challenges in GBM treatment
Reardon et al. 2014 -- Prognosis after GBM recurrence
Stupp et al. 2017 -- Tumor treating fields in GBM
Klein et al. 2012 -- Cognitive decline in GBM patients
Epstein & Street 2007 -- Communication and informed consent
ASCO 2017 -- Guidelines on prognosis disclosure
Mack et al. 2010 -- Oncologists’ attitudes toward prognosis disclosure
Clayton et al. 2008 -- Prognostic awareness in cancer patients
Hagerty et al. 2005 -- Barriers to prognostic communication
Shen et al. 2014 -- Prognostic awareness in malignant glioma
O’Donnell et al. 2016 -- Patient understanding of GBM prognosis
Beauchamp & Childress 2013 -- Principles of biomedical ethics
Jonsen et al. 2010 -- Clinical ethics methodology
Fallowfield et al. 2002 -- Historical trends in prognosis disclosure
Temel et al. 2012 -- Timing of prognosis discussions in cancer
Weeks et al. 2012 -- Physician communication of prognosis
Back et al. 2009 -- Use of prognosis to influence treatment decisions
Snyder et al. 2010 -- Definition and measurement of hope
Herth 1991 -- Hope scale development
Snyder et al. 1991 -- Hope theory
Lopez et al. 2014 -- Hope and health outcomes
Breitbart et al. 2010 -- Hope, meaning, and purpose in cancer
